scholarly journals Potential Prophylactic Treatments for COVID-19

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1292
Author(s):  
Noam Ben-Zuk ◽  
Ido-David Dechtman ◽  
Itai Henn ◽  
Libby Weiss ◽  
Amichay Afriat ◽  
...  
Keyword(s):  
World Health ◽  
Pharmaceutical Drugs ◽  
Mild Disease ◽  
Clinical Background ◽  
Repurposed Drugs ◽  
Prophylactic Use ◽  
Health Organization ◽  
Medical Indications ◽  
Respiratory Droplets ◽  
Near Future

The World Health Organization declared the SARS-CoV-2 outbreak a Public Health Emergency of International Concern at the end of January 2020 and a pandemic two months later. The virus primarily spreads between humans via respiratory droplets, and is the causative agent of Coronavirus Disease 2019 (COVID-19), which can vary in severity, from asymptomatic or mild disease (the vast majority of the cases) to respiratory failure, multi-organ failure, and death. Recently, several vaccines were approved for emergency use against SARS-CoV-2. However, their worldwide availability is acutely limited, and therefore, SARS-CoV-2 is still expected to cause significant morbidity and mortality in the upcoming year. Hence, additional countermeasures are needed, particularly pharmaceutical drugs that are widely accessible, safe, scalable, and affordable. In this comprehensive review, we target the prophylactic arena, focusing on small-molecule candidates. In order to consolidate a potential list of such medications, which were categorized as either antivirals, repurposed drugs, or miscellaneous, a thorough screening for relevant clinical trials was conducted. A brief molecular and/or clinical background is provided for each potential drug, rationalizing its prophylactic use as an antiviral or inflammatory modulator. Drug safety profiles are discussed, and current medical indications and research status regarding their relevance to COVID-19 are shortly reviewed. In the near future, a significant body of information regarding the effectiveness of drugs being clinically studied for COVID-19 is expected to accumulate, in addition to information regarding the efficacy of prophylactic treatments.

Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS

2020 ◽  
pp. 276-289
Author(s):  
Mobina Fathi ◽  
Kimia Vakili ◽  
Niloofar Deravi
Keyword(s):  
Pregnant Women ◽  
Intrauterine Growth Retardation ◽  
Negative Impact ◽  
World Health ◽  
Wuhan City ◽  
Intrauterine Growth ◽  
Exponential Increase ◽  
The World ◽  
Health Organization ◽  
Respiratory Droplets

Around the end of December 2019, a new beta-coronavirus from Wuhan City, Hubei Province, China began to spread rapidly. The new virus, called SARS-CoV-2, which could be transmitted through respiratory droplets, had a range of mild to severe symptoms, from simple cold in some cases to death in others. The disease caused by SARS-CoV-2 was named COVID-19 by WHO and has so far killed more people than SARS and MERS. Following the widespread global outbreak of COVID-19, with more than 132758 confirmed cases and 4955 deaths worldwide, the World Health Organization declared COVID-19 a pandemic disease in January 2020. Earlier studies on viral pneumonia epidemics has shown that pregnant women are at greater risk than others. During pregnancy, the pregnant woman is more prone to infectious diseases. Research on both SARS-CoV and MERS-CoV, which are pathologically similar to SARS-CoV-2, has shown that being infected with these viruses during pregnancy increases the risk of maternal death, stillbirth, intrauterine growth retardation and, preterm delivery. With the exponential increase in cases of COVID-19 throughout the world, there is a need to understand the effects of SARS-CoV-2 on the health of pregnant women, through extrapolation of earlier studies that have been conducted on pregnant women infected with SARS-CoV, and MERS-CoV. There is an urgent need to understand the chance of vertical transmission of SARS-CoV-2 from mother to fetus and the possibility of the virus crossing the placental barrier. Additionally, since some viral diseases and antiviral drugs may have a negative impact on the mother and fetus, in which case, pregnant women need special attention for the prevention, diagnosis, and treatment of COVID-19.

Outbreak of coronavirus disease 2019 (COVID-19) and its manifestation

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Bikash Debnath ◽  
Waikhom Somraj Singh ◽  
Kuntal Manna
Keyword(s):  
Antiviral Drug ◽  
World Health ◽  
Family Welfare ◽  
Pregnant Mother ◽  
Vaccine Candidates ◽  
The World ◽  
Mode Of Transmission ◽  
Health Organization ◽  
Effective Drugs ◽  
Respiratory Droplets

: The coronavirus disease 2019 (COVID-19) first outbreak in Wuhan, China, and the infection is intense worldwide. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for COVID-19. The World Health Organization (WHO) confirmed total deaths had noted 4.20% globally (March 21, 2020). Between the intervals of four months (July 21, 2020), confirmed total deaths had recorded 4.17%, globally. In India, 909 confirmed cases and 19 deaths were reported by Health and Family Welfare, Government of India, March 28, 2020. Between the intervals of 123 days In India, 1638870 confirmed cases and 35684 deaths. COVID-19 can potentially spread from person to person through direct contact or respiratory droplets from coughing and sneezing. The most common symptoms are fever, dry cough, difficulty in breathing, and fatigue. A pregnant mother with COVID-19 has fewer chances to transfer this infection of her newborn babies. Children have less affected than an adult. A specific antiviral drug or vaccine has not been developed to cure the disease. Chloroquine, hydroxychloroquine, lopinavir, ritonavir, nafamostat, nitazoxanide, and remdesivir have effective drugs to treat COVID-19. Many vaccine candidates are under pre-clinical and clinical studies. In this review, we highlight the epidemiology, sign-symptoms, pathogenesis, mode of transmission, and effects of a pregnant mother with newborns, children, prevention, and drugs affective to COVID-19.

Recent developments and opportunities in fighting COVID-19

Coronaviruses ◽  
2020 ◽  
Vol 01 ◽  
Author(s):  
Vikram Rao ◽  
Subrat Kumar Bhattamisra
Keyword(s):  
World Health ◽  
Diagnostic Tools ◽  
Extensive Literature ◽  
Angiotensin Converting Enzyme 2 ◽  
Recent Developments ◽  
Therapeutic Molecules ◽  
Discharged Patients ◽  
Extensive Literature Search ◽  
Repurposed Drugs ◽  
Health Organization

Background: COVID-19, a Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) was first diagnosed in the patients from Wuhan, China in December 2019. Within couple of months of infection, it was declared as pandemic by World health organization. COVID-19 has become the most contagious infection with a serious threat to global health. In this review, we aimed to discuss the pathogenesis, diagnostics, current treatments and potential vaccines for COVID-19. Methods: An extensive literature search was conducted using keywords “COVID-19”; “Coronavirus”; “SARS-Cov-2”; “SARS” in public domains of Google, Google scholar, PubMed, and ScienceDirect. Selected articles were used to construct this review. Results: SARS-Cov-2 uses the Spike (S) protein on its surface to recognize the receptor on angiotensin-converting enzyme 2 (ACE2) and bind with 10-folds greater affinity than SARS-Cov-1. Molecular assays and immunoassays are the most frequently used tests whereas computed tomography (CT) scans, Artificial intelligence enabled diagnostic tools were also used in patients. In therapeutic treatment, few drugs were repurposed and there are 23 therapeutic molecules including the repurposed drugs are in different stages of clinical trial. Similarly, development of vaccines is also in the pipeline. Few countries have managed well to contain the spread by rapid testing and identifying the clusters. Conclusion: Till now, the acute complications and mortality of COVID-19 has been linked to the pre-existing comorbid conditions or age. Besides the development of therapeutic strategies that includes drugs and vaccine, the long term implication of COVID-19 infection in terms of the disorder/disability in the cured/discharged patients is a new area to investigate.

scholarly journals Occupational health risk among healthcare workers during COVID-19 pandemic: actions to limit the risk

2021 ◽  
Vol 96 (1) ◽  
Author(s):  
Eman Casper
Keyword(s):  
Occupational Health ◽  
Health Risk ◽  
Healthcare Workers ◽  
World Health ◽  
High Morbidity ◽  
Wuhan City ◽  
Coronavirus Infection ◽  
Health Organization ◽  
Respiratory Droplets ◽  
Very High

AbstractThe World Health Organization declared coronavirus infection 2019 (COVID-19) as a pandemic in March 2020. The infection with coronavirus started in Wuhan city, China, in December 2019. As of October 2020, the disease was reported in 235 countries. The coronavirus infection 2019 (COVID-19) is a disease with high morbidity and mortality. As of February 2021, the number of confirmed cases of COVID-19 globally is 102,942,987 and 2,232,233 deaths according to WHO report. This infection is caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which is a ribonucleic acid (RNA) β-coronavirus. The infection is mainly transmitted through respiratory droplets.Healthcare workers (HCWs) play an essential role at the front lines, providing care for patients infected with this highly transmittable disease. They are exposed to very high occupational health risk as they frequently contact the infective persons. In order to limit the number of infected cases and deaths among healthcare workers, it is crucial to have better awareness, optimistic attitude, efficient PPE, and adequate health practices about COVID-19.

Aftermath of Covid -19 Pandemic in the community

2021 ◽  
pp. 498-500
Author(s):  
Sholly. CK
Keyword(s):  
World Health Organization ◽  
Antiviral Treatment ◽  
World Health ◽  
Health Concern ◽  
Severe Illness ◽  
Respiratory Illnesses ◽  
The World ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Respiratory Droplets

Novel corona virus (COVID-19) is an infectious condition, which can be spread directly or indirectly from one person to another and causes respiratory illnesses, range from common cold to acute respiratory syndrome. The first cases of this virus were found in Wuhan, China. According to the World Health Organization, COVID-19 is serious health concern and has higher risk for severe illness and spreading rapidly all over the world.This novel coronavirus was named Coronavirus Disease 2019 (COVID-19) by WHO in February 2020. The World Health Organization (WHO) has declared the coronavirus disease 2019 a pandemic, in the year2020 March. A global coordinated effort is needed to stop the further spread of the virus. Among all cases about 92% of the confirmed cases were recorded from China. Initial reports suggest that death rate ranges from 1% to 2% which varies in the study and country. The most of the death have occurred in patients over 50 years of age followed by young children. For the confirmed cases which included both laboratory and clinically diagnosed till now there is no specific antiviral treatment recommended but there is vaccine currently available. Once the virus develops in people, corona viruses can be spread from person to person through respiratory droplets. The viral material hangs out in these droplets and can be breathed into the respiratory tract, where the virus can then lead to an infection. Repercussions of Covid -19 on individuals, families and on front line warriors are countless1.

scholarly journals Preliminary study of coronavirus disease 2019 on pets in pandemic in Denpasar, Bali, Indonesia

2021 ◽  
pp. 2979-2983
Author(s):  
Hamong Suharsono ◽  
Ali Ghufron Mukti ◽  
Ketut Suryana ◽  
I. Wayan Masa Tenaya ◽  
Dilasdita Kartika Pradana ◽  
...  
Keyword(s):  
Close Contact ◽  
Genetic Material ◽  
Rna Isolation ◽  
World Health ◽  
Intermediate Hosts ◽  
Rt Pcr ◽  
Pcr Products ◽  
Preliminary Study ◽  
Health Organization ◽  
Respiratory Droplets

Background and Aim: Coronavirus disease 2019 (COVID-19) is an acute infectious respiratory disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and has spread rapidly globally, resulting in a pandemic. In humans, the main routes of transmission are respiratory droplets and close contact with infected individuals or through contact with an object infected with the virus, followed by touching mouth, nose, or eyes. It is assumed that SARS-CoV-2 was originated in wild animals and was then transmitted to humans. Although some wildlife and domestic animals can be naturally or experimentally infected with the virus, the intermediate hosts that transmitted it to humans are still unknown. Understanding the dynamics of SARS-CoV-2 associated with possible zoonotic transmission of intermediate hosts is considered critical. Reportedly, cats or dogs living with COVID-19-positive humans tested positive for the disease, suggesting that the virus was transmitted to the animals from humans. Information regarding the epidemiological investigation and comprehensive studies is limited. Therefore, it is still unclear how high is the correlation of infection in humans and pet animals, especially those living together. The aim of this study was to investigate the possibility of SARS-CoV-2 infection in the pets of patients with COVID-19 who were hospitalized at the Wangaya hospital, Denpasar, Bali, Indonesia. Materials and Methods: A total of seven clinically asymptomatic pets (six dogs of different races and sexes and a cat [age, 360-2920 days]) were included in this study. These animals belonged to patients with confirmed SARS-CoV-2 infection from August to November 2020. Nasal swab and nasopharyngeal samples were collected from the pets individually under anesthetic condition and were collected 6-12 days after confirmed SARS-CoV-2 infection in owners and hospitalization at the Wangaya Hospital. The swab samples were then processed for RNA isolation and tested using reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2, in accordance with the World Health Organization manual 2020. Results: RT-PCR results for all seven RNA samples, prepared from the swab samples, were negative. For the samples, all PCR products were below the threshold limit, suggesting no genetic material belonging to the samples tested. Conclusion: This was the first preliminary study of COVID-19 on pets in pandemic using RT-PCR. The study tested a very limited quantity of samples, and all of them were negative. However, the way in which the samples were prepared was considered appropriate. Therefore, in further studies, testing of more samples of pets of more individuals with confirmed SARS-CoV-2 infection is required.

scholarly journals Tuberculosis: Development of New Drugs and Treatment Regimens

2021 ◽  
Vol 7 (1) ◽  
pp. 36
Author(s):  
Soedarsono Soedarsono
Keyword(s):  
Treatment Guidelines ◽  
New Drugs ◽  
World Health ◽  
Health Crisis ◽  
Treatment Regimens ◽  
Tb Treatment ◽  
Repurposed Drugs ◽  
Latent Tb Infection ◽  
Health Organization ◽  
Who Guideline

Tuberculosis (TB) still becomes a public health crisis. Drug-resistant TB (DR-TB) becomes a concern as the increasing DR-TB cases in countries with high TB burden. The 2017 World Health Organization (WHO) guideline recommended a combination of TB treatment consisting of 2 months of intensive phase with isoniazid (H), rifampisin (R), pyrazinamid (Z), and ethambutol (E), followed by 4 months of continuation phase with HR daily. WHO has updated DR-TB treatment guidelines several times. In 2016, WHO recommended shorter regimen and individual regimen based on certain conditions. The most updated 2020 WHO guideline recommended the short regimen consisting of all oral drugs as well as changes in the grouping of medicines used in DR-TB regimens in longer/individual regimens. Bedaquiline, delamanid, pretomanid, and sutezolid are new drugs which have been studied for their uses as anti-TB drugs (ATD). Bedaquilin and delamanid, which have passed phase 3 trials, have been approved and recommended by WHO for DR-TB treatment. Repurposed drugs have been used for DR-TB treatment during the time of evaluation of drugs list and regimens for DR-TB treatment. Fluoroquinolones, clofazimine, linezolid, carbapenem, amoxicillin/clavulanic acid are repurposed drugs. TB and DR-TB management will be updated at any time, based on the latest findings in studies, to evaluate and improve the effectiveness of current treatments. Prevention of active TB disease by the treatment of latent TB infection (LTBI) is also a critical component of the end TB strategy by WHO. Therefore, the development of new drugs for the LTBI treatment is also needed.

Pediatric Brain Tumors

2017 ◽  
Author(s):  
Vijay Ramaswamy ◽  
Jason T. Huse ◽  
Yasmin Khakoo
Keyword(s):  
Rare Variants ◽  
Pediatric Population ◽  
Pediatric Brain Tumors ◽  
World Health ◽  
Who Grade ◽  
Pilocytic Astrocytomas ◽  
Aggressive Histology ◽  
Malignant Lesions ◽  
Health Organization ◽  
Near Future

Cerebellar astrocytoma of childhood most commonly refers to cerebellar pilocytic astrocytoma, a World health Organization (WHO) Grade I tumor. However, on occasion cerebellar astrocytomas may demonstrate more aggressive histology including fibrillary astrocytomas, pilomyxoid astrocytomas, and rarely malignant lesions. In the near future, the diagnosis of cerebellar astrocytomas will be simplified by molecular analysis for BRAF fusions rather than a purely morphological approach. The emergence of next-generation sequencing can be expected to identify single nucleotide variations and further expand our understanding of both pilocytic astrocytomas as well as rare variants that occur in the cerebellum. Therapies targeting BRAF (B-raf protooncogene) are currently in clinical trial for adult malignancies and will eventually reach the pediatric population, allowing a targeted approach to recurrent and surgically inaccessible cases of pilocytic astrocytomas.

scholarly journals Multidrug-resistant tuberculosis infection and disease in children: a review of new and repurposed drugs

2019 ◽  
Vol 6 ◽  
pp. 204993611986473 ◽  
Author(s):  
Julie Huynh ◽  
Ben J. Marais
Keyword(s):  
Clinical Care ◽  
Multidrug Resistant ◽  
World Health ◽  
Resistant Tuberculosis ◽  
Multidrug Resistant Tuberculosis ◽  
Resource Limited ◽  
Prevention And Treatment ◽  
Mdr Tb ◽  
Repurposed Drugs ◽  
Health Organization

The World Health Organization estimates that 10 million new cases of tuberculosis (TB) occurred worldwide in 2017, of which 600,000 were rifampicin or multidrug-resistant (RR/MDR) TB. Modelling estimates suggest that 32,000 new cases of MDR-TB occur in children annually, but only a fraction of these are correctly diagnosed and treated. Accurately diagnosing TB in children, who usually have paucibacillary disease, and implementing effective TB prevention and treatment programmes in resource-limited settings remain major challenges. In light of the underappreciated RR/MDR-TB burden in children, and the lack of paediatric data on newer drugs for TB prevention and treatment, we present an overview of new and repurposed TB drugs, describing the available evidence for safety and efficacy in children to assist clinical care and decision-making.

scholarly journals Historical Perspective of Traditional Indigenous Medical Practices: The Current Renaissance and Conservation of Herbal Resources

2014 ◽  
Vol 2014 ◽  
pp. 1-20 ◽  
Author(s):  
Si-Yuan Pan ◽  
Gerhard Litscher ◽  
Si-Hua Gao ◽  
Shu-Feng Zhou ◽  
Zhi-Ling Yu ◽  
...  
Keyword(s):  
Herbal Medicines ◽  
World Health ◽  
Pharmaceutical Drugs ◽  
Plant Resources ◽  
Healthcare Needs ◽  
Traditional Remedies ◽  
The World ◽  
Increasing Demand ◽  
Health Organization ◽  
Aging Societies

In recent years, increasing numbers of people have been choosing herbal medicines or products to improve their health conditions, either alone or in combination with others. Herbs are staging a comeback and herbal “renaissance” occurs all over the world. According to the World Health Organization, 75% of the world’s populations are using herbs for basic healthcare needs. Since the dawn of mankind, in fact, the use of herbs/plants has offered an effective medicine for the treatment of illnesses. Moreover, many conventional/pharmaceutical drugs are derived directly from both nature and traditional remedies distributed around the world. Up to now, the practice of herbal medicine entails the use of more than 53,000 species, and a number of these are facing the threat of extinction due to overexploitation. This paper aims to provide a review of the history andstatus quoof Chinese, Indian, and Arabic herbal medicines in terms of their significant contribution to the health promotion in present-day over-populated and aging societies. Attention will be focused on the depletion of plant resources on earth in meeting the increasing demand for herbs.

Sign in / Sign up

Export Citation Format

Share Document